Eli Lilly (LLY) Gets Price Target Boost as Analysts See Strong Mounjaro, Zepbound Sales

Eli Lilly & Company (NYSE:LLY) ranks among the best low volatility stocks to buy according to analysts. On July 11, Guggenheim reiterated its Buy rating on Eli Lilly & Company (NYSE:LLY) ahead of the company’s second-quarter earnings report and increased its price target from $936 to $942.

In contrast to the consensus predictions of $4.39 billion from VisibleAlpha and $4.89 billion from FactSet, the firm projects second-quarter Mounjaro sales of $4.49 billion. Guggenheim also predicts that Zepbound will rake in $3.10 billion in US sales in the second quarter, which is marginally more than the $2.94 billion consensus estimate.

Guggenheim’s modified model also takes into account a projected $0.14 effect on earnings per share from second-quarter IPR&D, as well as improved tirzepatide expectations based on prescription analysis.

The firm also emphasized that investors are paying close attention to net price and prescription trends for tirzepatide, as well as a number of important clinical trial readouts scheduled through the end of 2025.

Eli Lilly & Company (NYSE:LLY) is a major global pharmaceutical company that develops, manufactures, and distributes a wide range of drugs. Founded in 1876, it has grown to become one of the world’s largest pharmaceutical companies.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds

Disclosure: None.